DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81

DAIC

APRIL 30, 2024

The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Open Heart

JULY 20, 2022

Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001). ±4 months.

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

Open Heart

JULY 17, 2023

to 5.12; p=0.049), chronic kidney disease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68 Results The combined end point of death and emergency cardiovascular hospitalisation occurred in 70 (36.3%) of 193 patients with a postponed cardiovascular intervention.

COVID-19 52

COVID-19 Outcomes Cardiovascular Interventions Risk Factors 52

Circulation

NOVEMBER 11, 2024

Patient did not report any symptoms and was hemodynamically stable. He was euvolemic on physical exam.

Bradycardia 40

Bradycardia Coronary Artery Disease Kidney Disease Outpatient 40

Stroke Journal

FEBRUARY 1, 2024

vs. 6.9%, SD 0.1), chronic kidney disease (1.9% This finding sets the stage for future work leveraging both outpatient and pharmacy-based claims to further explore this finding. Patients with migraine were younger (40.2±15.2 standardized difference (SD) 0.38), more likely to be female (81.4% vs. 5.1%, SD 0.12).

Strokes 40

Strokes Stroke Document Kidney Disease 40